Free tool
Drug literature search
Last checked: Nov 20, 2026Source: PubMed, Europe PMC, OpenAlex
232 results in PubMed
Peer-reviewed biomedical literature from the US National Library of Medicine, most relevant first. Showing the first 25. Limited to clinical trials, meta-analyses and systematic reviews.
- Classification and Genotype-Phenotype Relationships of GBA1 Variants: MDSGene Systematic Review.
Rossi M, Schaake S, Usnich T, et al. · Mov Disord · 2025Systematic Review, Research Support, Non-U.S. Gov't
- Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials.
Heier JS, Lad EM, Holz FG, et al. · Lancet · 2023Randomized Controlled Trial, Clinical Trial, Phase III
- Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: results from the 2-year randomised phase III BALANCE study.
Wallace EL, Goker-Alpan O, Wilcox WR, et al. · J Med Genet · 2024Randomized Controlled Trial, Clinical Trial, Phase III
- Clinical and preclinical insights into high-dose ambroxol therapy for Gaucher disease type 2 and 3: A comprehensive systematic review.
den Hollander B, Le HL, Swart EL, et al. · Mol Genet Metab · 2024Systematic Review
- The Mini-COMET Clinical Trial: Safety and Efficacy of Avalglucosidase Alfa after 97 Weeks of Treatment in Children with Infantile-Onset Pompe Disease Previously Treated with Alglucosidase Alfa.
Kronn D, Davison J, Broomfield A, et al. · J Pediatr · 2025Clinical Trial, Phase II, Multicenter Study
- Management of Chronic Subdural Hematoma With Adjunctive Embolization of Middle Meningeal Artery: The EMMA-Can Randomized Clinical Trial.
Shankar JJS, Alcock S, Kashani N, et al. · JAMA · 2026Comparative Study, Multicenter Study
- Phase I study of liver depot gene therapy in late-onset Pompe disease.
Smith EC, Hopkins S, Case LE, et al. · Mol Ther · 2023Clinical Trial, Phase I, Research Support, N.I.H., Extramural
- 104-week efficacy and safety of cipaglucosidase alfa plus miglustat in adults with late-onset Pompe disease: a phase III open-label extension study (ATB200-07).
Schoser B, Kishnani PS, Bratkovic D, et al. · J Neurol · 2024Clinical Trial, Phase III, Randomized Controlled Trial
- Efficacy and safety of avalglucosidase alfa in patients with late-onset Pompe disease after 145 weeks of treatment during the COMET trial.
Kishnani PS, Díaz-Manera J, Illarioshkin S, et al. · J Neurol · 2025Randomized Controlled Trial, Clinical Trial, Phase III
- What's new and what's next for gene therapy in Pompe disease?
Roger AL, Sethi R, Huston ML, et al. · Expert Opin Biol Ther · 2022Systematic Review, Research Support, N.I.H., Extramural
- Switching treatment to cipaglucosidase alfa plus miglustat positively affects patient-reported outcome measures in patients with late-onset Pompe disease.
Kishnani PS, Byrne BJ, Claeys KG, et al. · J Patient Rep Outcomes · 2024Randomized Controlled Trial, Clinical Trial, Phase III
- Gaucher disease and bone manifestations.
Marcucci G, Zimran A, Bembi B, et al. · Calcif Tissue Int · 2014Research Support, Non-U.S. Gov't, Systematic Review
- Hematopoietic stem cell transplantation for Gaucher disease.
Somaraju UR, Tadepalli K · Cochrane Database Syst Rev · 2017Research Support, Non-U.S. Gov't, Systematic Review
- Global Epidemiology of Gaucher Disease: an Updated Systematic Review and Meta-analysis.
Wang M, Li F, Zhang J, et al. · J Pediatr Hematol Oncol · 2023Meta-Analysis, Systematic Review
- Sphingolipids in Gaucher disease: a systematic review.
Lake A, Fuller M · Orphanet J Rare Dis · 2025Systematic Review, Research Support, Non-U.S. Gov't
- A Systematic Review and Meta-analyses of Longitudinal Studies on Drug Treatments for Gaucher Disease.
Leonart LP, Fachi MM, Böger B, et al. · Ann Pharmacother · 2023Meta-Analysis, Systematic Review
- Immune Tolerance-Adjusted Personalized Immunogenicity Prediction for Pompe Disease.
De Groot AS, Desai AK, Lelias S, et al. · Front Immunol · 2021Clinical Trial, Research Support, N.I.H., Extramural
- Gaucher: A Systematic Review on Oral and Radiological Aspects.
Minervini G, Franco R, Marrapodi MM, et al. · Medicina (Kaunas) · 2023Systematic Review
- Patient-reported outcomes in Gaucher's disease: a systematic review.
Feng J, Gao Z, Shi Z, et al. · Orphanet J Rare Dis · 2023Systematic Review, Research Support, Non-U.S. Gov't
- Lysosomal storage disease as an etiology of nonimmune hydrops.
Gimovsky AC, Luzi P, Berghella V · Am J Obstet Gynecol · 2015Systematic Review
- Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Oral Venglustat in Healthy Volunteers.
Peterschmitt MJ, Crawford NPS, Gaemers SJM, et al. · Clin Pharmacol Drug Dev · 2021Clinical Trial, Phase I, Randomized Controlled Trial
- Neuroimaging in Glucocerebrosidase-Associated Parkinsonism: A Systematic Review.
Filippi M, Balestrino R, Basaia S, et al. · Mov Disord · 2022Systematic Review, Research Support, Non-U.S. Gov't
- Neurological symptoms in adults with Gaucher disease: a systematic review.
Imbalzano G, Ledda C, Romagnolo A, et al. · J Neurol · 2024Systematic Review
- Gaucher disease: a systematic review and meta-analysis of bone complications and their response to treatment.
Piran S, Amato D · J Inherit Metab Dis · 2010Meta-Analysis, Research Support, Non-U.S. Gov't
- Long-term efficacy and safety of vestronidase alfa enzyme replacement therapy in pediatric subjects < 5 years with mucopolysaccharidosis VII.
Lau HA, Viskochil D, Tanpaiboon P, et al. · Mol Genet Metab · 2022Clinical Trial, Phase II, Multicenter Study
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.